Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.

Sergio CedilloCarla GaríSusana AceitunoLuis MansoAna Cristina Cercos LletiPedro Ventayol BoschAntonio CasadoJosé Alejandro Pérez-Fidalgo

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

For patients with homologous recombination deficiency-positive advanced ovarian cancer, olaparib plus bevacizumab is a cost-effective maintenance therapy compared with bevacizumab alone in Spain.

Keyphrases

dna repair
metastatic colorectal cancer
dna damage
replacement therapy
stem cells
clinical trial
randomized controlled trial
combination therapy
open label
smoking cessation
cell therapy
study protocol